Trio Pharmaceuticals & Ajinomoto Bio-Pharma Services Enter Development Collaboration for a Novel Antibody Therapeutic

Trio Pharmaceuticals, Inc. and Ajinomoto Bio-Pharma Services recently announced a development collaboration agreement to evaluate AJICAP, a proprietary site-specific conjugation technology offered by Aji Bio-Pharma for the development of TDCs. The AJICAP technology will be used to conjugate a cytotoxic payload to TRIO’s lead oncology candidate with TRIO evaluating functionality of the TDC.

TDCs are a first-in-class ADC with dual functionality. TRIO’s dual action TDC utilizes targeted payload delivery to stop both tumor growth and immunosuppression. By generating a less immunosuppressive tumor microenvironment, TDC enhances activation of tumor-specific immune effector cells further facilitating cancer cell destruction.

AJICAP is a robust site-specific conjugation technology compatible with varied antibody modalities. AJICAP’s advantage is its “off-the-shelf” feature, allowing any antibody drug at any stage of development to be conjugated to drug-payloads of choice without the need to modify the sequence. In contrast to traditional Cys-maleimide and Lys-succinimide conjugation technologies, AJICAP conjugation is robust and generates ADCs with high yields.

“We are very excited to collaborate with Aji Bio-Pharma for evaluating AJICAP to develop our proprietary dual action TDC. The AJICAP conjugation technology marks a new beginning in the ADC field, allowing generation of ADCs with site-specific conjugation without change in antibody sequence, a rate-limiting step in the development of site-specific ADCs. Setting an early collaboration with Aji Bio-Pharma will ease our cGMP plans for clinical development,” noted Dr. Shiva Bhowmik, Founder and CEO of Trio Pharmaceuticals, Inc.

Dr. Brian Mendelsohn, Director, Process Development and Technology Transfer at Aji Bio-Pharma stated, “AJICAP was developed to create novel ADCs with therapeutic window enhancements, while shortening the development timeline. We are excited to collaborate with TRIO as they advance TDC technology, developing a new class of ADCs. This collaboration marks a new avenue of development in the ADC field.” Dr. Tatsuya Okuzumi, Associate General Manager, Business Development, Ajinomoto Co, Inc., added, “We are very excited to collaborate with TRIO in the development of dual action ADCs. As a member of the Ajinomoto Group, Aji Bio-Pharma houses a talented and dedicated team of ADC scientists and strong CMC capabilities, which will benefit TRIO’s development of this novel ADC.”

Trio Pharmaceuticals, Inc. (TRIO) is a privately held cancer therapeutics company incubating at QB3, University of California San Francisco. TRIO is developing first-in-class dual action antibody drug conjugates, TRIObody Drug Conjugate (TDC), and dual action antibody drugs, TRIObody, that stops both tumor growth and immunosuppression with and without payload delivery, respectively. TRIObody and TDC can synergize with current cancer drugs to improve efficacy.

More information on TRIO Pharmaceuticals, Inc.
Shiva Bhowmik, PhD, CEO
shiva@triopharmaceuticals.com |(765) 490-0874

Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India, providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. Ajinomoto and Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including Corynex protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client’s needs. Ajinomoto Bio-Pharma Services is a member of the Ajinomoto Group. Learn more: www.AjiBio-Pharma.com